#1 Clinical Trials Search in Europe

Follicle centre lymphoma follicular grade I II – III refractory – Diagnostics

Go back

Diagnosing refractory follicular lymphoma—especially grades I, II, or III that have stopped responding to treatment—requires careful examination and specialized testing to guide the next steps in care and understand how the disease is behaving in your body.

Introduction: Who Should Seek Diagnostics and When

Follicular lymphoma is a type of cancer that affects white blood cells called B lymphocytes, which are an important part of your immune system that helps fight infections. This cancer develops slowly in most cases, but it can come back after treatment or stop responding to therapy altogether. When this happens, we call it refractory or relapsed follicular lymphoma.[1]

People with follicular lymphoma should seek further diagnostic testing whenever they notice symptoms returning after a period of feeling well, or when symptoms never fully went away despite treatment. Common warning signs include painless swelling of lymph nodes in the neck, armpits, or groin that doesn’t go away, persistent fatigue that interferes with daily activities, unexplained weight loss (especially losing 10 percent or more of your body weight without trying), fever without signs of infection, and night sweats that soak your sheets.[2][3]

It’s especially important to see your doctor if these symptoms develop within the first two years after completing chemotherapy or within 12 months after treatment with a drug called rituximab. Research shows that people whose disease returns this quickly may have a more challenging course ahead, with a five-year survival rate of around 50 percent compared to those whose disease stays quiet for longer.[1] Early detection of relapse or refractory disease allows your medical team to adjust your treatment plan and possibly enroll you in clinical trials testing newer therapies.

⚠️ Important
Not everyone with relapsed follicular lymphoma needs immediate treatment. If your disease comes back but you feel well and have no symptoms, your doctor may suggest an approach called “active surveillance” or “watch and wait.” This means monitoring your condition closely through regular checkups, blood tests, and imaging, starting treatment only when symptoms appear or tests show the disease is getting worse.[1]

Even if you don’t have symptoms but your routine follow-up tests show concerning changes—such as rapidly growing lymph nodes, rising levels of a substance called lactate dehydrogenase (LDH) in your blood, or signs that the cancer is affecting your bone marrow—your doctor may recommend diagnostic testing to better understand what’s happening.[7] Sometimes follicular lymphoma can transform into a more aggressive type of lymphoma called diffuse large B-cell lymphoma, and catching this early is crucial for treatment planning.[5]

Diagnostic Methods for Identifying and Distinguishing the Disease

Physical Examination and Medical History

When you visit your doctor with concerns about follicular lymphoma, the first step is always a thorough physical examination. Your doctor will carefully feel areas of your body where lymph nodes are located—particularly your neck, armpits, groin, and abdomen—checking for any enlarged or swollen nodes. Follicular lymphoma typically causes painless swelling, which sets it apart from infections that usually make lymph nodes tender and sore.[6][7]

During this exam, your doctor will also check whether your spleen or liver feels larger than normal by gently pressing on your abdomen. An enlarged spleen can be a sign that lymphoma has spread beyond the lymph nodes. Your doctor will ask detailed questions about your symptoms: When did they start? Have you noticed fever, night sweats, or weight loss? Have you felt more tired than usual? These questions help paint a picture of how the disease might be affecting your body and whether it’s growing more aggressively.[3][17]

Lymph Node Biopsy

The most definitive way to diagnose follicular lymphoma—and to determine whether it has returned or changed—is through a lymph node biopsy. This procedure involves removing all or part of a swollen lymph node so that specialists can examine the tissue under a microscope. If a lymph node is easy to reach, your surgeon may remove the entire node. If it’s located deeper in your body, a special needle may be used to take a small sample through your skin, a technique called fine-needle aspiration.[2][17]

In the laboratory, experts look at the pattern of cell growth within the lymph node. Follicular lymphoma gets its name because the abnormal cells typically grow in clusters called follicles, which look like small round formations reminiscent of normal structures in lymph nodes called germinal centers. The specialist will also count how many large abnormal cells, called centroblasts, are present compared to smaller cells called centrocytes. This count determines the grade of your follicular lymphoma—grades I and II have fewer large cells and grow more slowly, while grade III has more large cells and may behave more aggressively.[5][13]

Because follicular lymphoma can sometimes transform into a faster-growing lymphoma, a new biopsy is often recommended if your disease relapses, especially if your symptoms seem worse than before or if you develop new symptoms like rapidly growing lumps, fever, or sudden weight loss. The biopsy can reveal whether the cancer cells have changed their appearance or behavior, which would change your treatment plan.[1]

Blood Tests

Blood tests are an essential part of diagnosing and monitoring follicular lymphoma. Your doctor will order a complete blood count (CBC) to measure the levels of different types of blood cells in your body. Follicular lymphoma can affect your bone marrow, where blood cells are made, so you might have low red blood cells (causing anemia and fatigue), low white blood cells (increasing infection risk), or low platelets (which help your blood clot).[7][8]

Another important blood test measures lactate dehydrogenase (LDH), an enzyme that can be elevated when lymphoma cells are growing rapidly or when the cancer is transforming into a more aggressive type. Higher LDH levels may signal that your disease is becoming more difficult to control.[7][17]

Your doctor may also test your kidney and liver function, as lymphoma can sometimes affect these organs, and their health is important for determining which treatments you can safely receive. Blood tests can also help rule out infections or other conditions that might cause similar symptoms, like mononucleosis or other viral illnesses that can make lymph nodes swell temporarily.[1]

Imaging Tests

Imaging tests create detailed pictures of the inside of your body, helping doctors see where lymphoma is located and how much of your body it affects. The most commonly used imaging tests for follicular lymphoma are computed tomography (CT) scans and positron emission tomography (PET) scans.[6][8]

A CT scan uses X-rays taken from many angles to create cross-sectional images of your body, like slices of bread in a loaf. It can show enlarged lymph nodes in your chest, abdomen, and pelvis—areas where follicular lymphoma commonly spreads. A PET scan uses a small amount of radioactive sugar that cancer cells absorb more readily than normal cells. The scanner then creates images showing “hot spots” where the sugar has concentrated, revealing active cancer. Doctors often combine PET and CT scans into one test (called a PET-CT scan) to get both anatomical and metabolic information about your lymphoma.[17]

These imaging tests are particularly useful for comparing how your disease looks now versus how it looked after your last treatment. If lymph nodes that had shrunk with treatment are now growing again, or if new areas of involvement appear, this indicates relapsed disease. If lymph nodes never fully shrank or are growing during treatment, this suggests refractory disease.[1]

Bone Marrow Biopsy

A bone marrow biopsy involves taking a small sample of the soft, spongy tissue inside your bones where blood cells are made. This test helps determine whether follicular lymphoma has spread to your bone marrow, which happens in a significant number of patients. The procedure is usually done on your hip bone. Your doctor will numb the area and use a special needle to collect a tiny core of bone marrow tissue and some liquid bone marrow.[17][7]

Examining bone marrow under the microscope can reveal whether lymphoma cells are present and how many there are. Bone marrow involvement is important for staging your disease—knowing how far it has spread—and can also explain symptoms like anemia, fatigue, or frequent infections if the cancer cells are crowding out normal blood-forming cells.[5][8]

Immunophenotyping and Molecular Tests

Once tissue samples are collected, specialized laboratory tests help confirm the diagnosis and understand the biology of your lymphoma. Immunophenotyping uses antibodies to identify specific proteins on the surface of cancer cells. Follicular lymphoma cells typically express proteins called CD19, CD20, CD10, BCL2, and BCL6. These markers tell doctors that the cancer originated from B cells in the germinal center of lymph nodes and help distinguish follicular lymphoma from other types of lymphoma.[5][13]

Genetic and molecular testing looks for specific abnormalities inside cancer cells. About 85 to 90 percent of people with follicular lymphoma have a chromosomal change called t(14;18) translocation. This genetic swap causes cells to produce too much of a protein called BCL2, which prevents cancer cells from dying when they normally should. Identifying this translocation helps confirm the diagnosis, though its presence alone doesn’t mean you have cancer—some healthy people carry this genetic change in a small number of their cells without ever developing lymphoma.[1][5][8]

Other genetic tests look for mutations in genes with complex names like KMT2D, CREBBP, and EZH2, which are involved in controlling how genes are turned on and off. These so-called epigenetic mutations are common in follicular lymphoma and help scientists understand why the cancer develops. Some of these mutations may also predict how well certain newer treatments will work.[1][5]

Distinguishing Relapsed from Refractory Disease

Understanding whether your follicular lymphoma is relapsed or refractory requires looking at your treatment history and how your disease has responded over time. Relapsed disease means the lymphoma went away or shrank significantly after treatment (a state called remission) but then came back after a period of months or years. Refractory disease means the lymphoma never fully responded to treatment in the first place, or the response was so brief that it essentially didn’t work.[18]

Your doctor will review your previous imaging scans, blood tests, and biopsy results to compare your disease now with how it looked before and after treatment. If you had a complete disappearance of all signs of cancer that lasted for several years before symptoms returned, that’s relapsed disease. If your lymph nodes shrank only partially with treatment, or if they began growing again within a few weeks or months, that’s more consistent with refractory disease.[1][12]

The timing of relapse has important implications for your prognosis. Research has shown that people whose follicular lymphoma progresses within 24 months of starting chemotherapy, or within 12 months of treatment with rituximab, tend to have more aggressive disease and poorer outcomes. This is sometimes called early progression or progression of disease within 24 months (POD24), and identifying it helps doctors understand the urgency of finding effective treatment.[1][12][19]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments to find better ways to help patients with follicular lymphoma. If you have relapsed or refractory disease, your doctor may suggest enrolling in a clinical trial, especially if standard treatments have not worked well. However, clinical trials have specific requirements, called eligibility criteria, that determine who can participate. Diagnostic tests play a crucial role in determining whether you qualify.[12]

Confirming the Diagnosis and Disease Status

Before you can join a clinical trial for refractory follicular lymphoma, you’ll need to have your diagnosis confirmed through a biopsy that clearly shows follicular lymphoma. Trials typically require that the biopsy be recent—often within a few months—to ensure that your disease hasn’t transformed into a different type of lymphoma. Some trials specifically exclude patients whose follicular lymphoma has transformed into diffuse large B-cell lymphoma, while others may include both types.[1][12]

The biopsy tissue will undergo the same immunophenotyping and molecular tests described earlier to confirm that your lymphoma has the characteristics being studied in the trial. For example, a trial testing a drug that targets the CD20 protein will require that your lymphoma cells express CD20. A trial studying a drug aimed at cells with the BCL2 translocation will verify that your cancer has this genetic change.[5]

Staging and Disease Burden

Clinical trials often have requirements about the stage of your disease—how far it has spread through your body. Follicular lymphoma is staged from I to IV, with higher numbers indicating more widespread disease. Stage I means lymphoma is in just one group of lymph nodes, Stage II means it’s in two or more groups on the same side of your diaphragm (the muscle that separates your chest from your abdomen), Stage III means it’s on both sides of the diaphragm, and Stage IV means it has spread beyond lymph nodes to organs like the bone marrow, liver, or lungs.[7][15]

Most people with follicular lymphoma are diagnosed at Stage III or IV because the disease often doesn’t cause symptoms early on. Clinical trials for relapsed or refractory disease typically include patients with advanced-stage disease (Stage III or IV) since this represents the majority of people who need treatment.[8]

Some trials also measure disease burden, which refers to how much cancer is in your body. This might be assessed by counting how many lymph nodes are enlarged, measuring the size of the largest tumor, or looking at how much of your bone marrow is involved. CT scans and PET scans provide this information. Trials might require that you have a certain minimum disease burden to ensure that researchers can accurately measure whether the treatment is shrinking your tumors.[17]

Blood Tests and Organ Function

Before enrolling in a clinical trial, you’ll need blood tests to check how well your major organs are working. Trials typically require that your kidneys, liver, and bone marrow are functioning well enough that you can safely tolerate the experimental treatment. Blood tests will measure your levels of red blood cells, white blood cells, and platelets, as well as substances that indicate kidney function (like creatinine) and liver function (like bilirubin and liver enzymes).[17]

If your blood counts are very low because of lymphoma involvement in your bone marrow, or if your kidney or liver function is impaired, you may not qualify for certain trials. However, some trials are specifically designed for patients with these complications, so your doctor can help you find an appropriate study.[12]

Prior Treatment History

Clinical trials for relapsed or refractory follicular lymphoma typically require documentation of what treatments you’ve received previously and how your disease responded. You’ll need records showing that you received at least one prior line of therapy—often including an anti-CD20 antibody like rituximab combined with chemotherapy—and that your disease either didn’t respond adequately or came back after responding.[1][12]

Some trials are designed for patients who have received many prior treatments and have run out of standard options, while others are for patients who have received just one or two prior therapies. The trial investigators need to know your complete treatment history to ensure you’re eligible and to understand how experimental results might apply to other patients with similar experiences.[19]

Performance Status Assessment

Clinical trials assess your overall health and ability to function in daily life using a measure called performance status. The most common scales are the ECOG (Eastern Cooperative Oncology Group) scale, which ranges from 0 (fully active, able to do everything you did before cancer) to 4 (completely disabled, confined to bed or chair). Most trials require that participants have a performance status of 0, 1, or 2, meaning you can take care of yourself and be up and about for at least half of your waking hours.[1]

Your doctor will assess your performance status during your physical examination by asking about your daily activities, whether you can work, whether you need help with basic tasks like dressing or bathing, and how much time you spend in bed or sitting. This assessment helps ensure that you’re healthy enough to participate in the trial and tolerate the experimental treatment.[17]

Special Tests for Targeted Therapies

As treatments for follicular lymphoma become more personalized, some clinical trials test therapies that target specific genetic or molecular features of cancer cells. For these trials, you may need additional specialized testing beyond standard biopsies. For example, trials of drugs targeting the EZH2 protein mutation will require testing your tumor for this specific genetic change. Only patients whose lymphoma has the EZH2 mutation would qualify for such a trial.[1][12]

Some newer treatments called CAR T-cell therapy require that your own immune cells be collected, modified in a laboratory, and then returned to your body to fight the cancer. Before qualifying for such a trial, you’ll need tests to ensure that your immune system is producing enough healthy T-cells that can be collected and modified. This might involve blood tests that count different types of immune cells and assess their function.[18]

Prognosis and Survival Rate

Prognosis

The outlook for people with relapsed or refractory follicular lymphoma depends on several important factors. How quickly your disease came back after treatment is one of the strongest predictors of what lies ahead. About 20 percent of patients with follicular lymphoma experience disease progression within the first two years after starting chemotherapy. For this group, the prognosis is more challenging, with an overall five-year survival rate of approximately 50 percent.[1] People whose disease relapses within 24 months of chemotherapy or within 12 months of rituximab treatment are considered to have a poorer prognosis compared to those who experience longer remissions.[1][12]

Another important factor is whether your follicular lymphoma has transformed into a more aggressive type of cancer, particularly diffuse large B-cell lymphoma. This transformation occurs in a subset of patients and typically signals a more challenging course that requires more intensive treatment.[5] Other factors that influence prognosis include your age, overall health, how well your organs are functioning, the grade of your lymphoma (with grade III generally being more aggressive than grades I or II), how much of your body is affected by cancer, and the presence of certain genetic changes in your cancer cells.[13][15]

Despite these challenges, many people with relapsed or refractory follicular lymphoma can still live for many years with good quality of life. The disease often follows a pattern of responding to treatment, relapsing, and then responding to a different treatment. Each time the disease comes back, doctors have an array of treatment options to try, including newer targeted therapies and immunotherapies that weren’t available in the past. Even when the disease cannot be cured, it can often be controlled for extended periods, allowing people to continue their daily activities and spend time with loved ones.[1][7]

Survival Rate

Historically, the median survival for patients with follicular lymphoma has been approximately 8 to 10 years from the time of initial diagnosis. However, this statistic comes from data collected before many of today’s newer treatments became available. Since the introduction of rituximab, a targeted antibody therapy, overall survival has improved significantly, and current data suggests that survival continues to increase with newer treatment options.[8][11]

For people whose disease comes back or proves resistant to treatment, survival statistics vary based on when the relapse occurred. Those experiencing early progression—within the first 24 months after starting treatment—have a five-year survival rate of about 50 percent. In contrast, people whose disease remains in remission for longer periods before relapsing generally have better survival outcomes.[1][12]

More recent studies suggest that with modern treatments, including targeted therapies, immunotherapies, and CAR T-cell therapy, more than 90 percent of patients survive beyond five years from initial diagnosis. The median overall survival for follicular lymphoma is now estimated at 14 years or longer.[12] It’s important to remember that statistics are based on large groups of people and cannot predict exactly what will happen to any individual person. Your own outcome depends on your unique situation, including your specific disease characteristics, your response to treatment, and your overall health.[7]

Ongoing Clinical Trials on Follicle centre lymphoma follicular grade I II – III refractory

References

https://www.ncbi.nlm.nih.gov/books/NBK589677/

https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/follicular-lymphoma

https://www.mayoclinic.org/diseases-conditions/follicular-lymphoma/symptoms-causes/syc-20584732

https://www.vacancer.com/cancer/non-hodgkin-lymphoma/follicular-lymphoma/

https://pmc.ncbi.nlm.nih.gov/articles/PMC8743801/

https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/follicular-lymphoma/

https://my.clevelandclinic.org/health/diseases/22606-follicular-lymphoma

https://emedicine.medscape.com/article/203268-overview

https://www.ncbi.nlm.nih.gov/books/NBK589677/

https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/follicular-lymphoma

https://emedicine.medscape.com/article/203268-overview

https://pmc.ncbi.nlm.nih.gov/articles/PMC10028236/

https://www.hematologyandoncology.net/archives/june-2022/follicular-lymphoma-grade-3-a-comprehensive-review/

https://www.ncbi.nlm.nih.gov/books/NBK589677/

https://www.mylymphomateam.com/resources/understanding-stages-of-follicular-lymphoma

https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/follicular-lymphoma

https://www.mayoclinic.org/diseases-conditions/follicular-lymphoma/diagnosis-treatment/drc-20584747

https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/follicular-lymphoma/relapsedfl/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10028236/

https://www.webmd.com/cancer/lymphoma/follicular-lymphoma

https://oncpracticemanagement.com/special-issues/interview-with-the-innovators-follicular-lymphoma

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://pmc.ncbi.nlm.nih.gov/articles/PMC6558629/

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

More information about
Follicle centre lymphoma follicular grade I II – III refractory:

FAQ

What’s the difference between relapsed and refractory follicular lymphoma?

Relapsed follicular lymphoma means your cancer went away or shrank significantly after treatment (entered remission) but then came back after a period of months or years. Refractory disease means the lymphoma never fully responded to treatment in the first place, or it came back so quickly that the treatment essentially didn’t work. Your doctor determines which situation applies to you by comparing imaging scans and other test results from before treatment, after treatment, and now.[18]

Why do I need a new biopsy if I was already diagnosed with follicular lymphoma?

A new biopsy when your disease comes back helps doctors see if the cancer cells have changed. Follicular lymphoma can sometimes transform into a more aggressive type of lymphoma called diffuse large B-cell lymphoma, which would require different treatment. The biopsy can also confirm that what looks like cancer on imaging scans isn’t actually scar tissue from previous treatment or another condition. Fresh tissue also allows for newer molecular tests that might guide treatment choices.[1][5]

Do I always need a bone marrow biopsy to diagnose relapsed follicular lymphoma?

Not always. Your doctor will decide based on your individual situation. If imaging tests clearly show lymph node involvement and you have symptoms, your doctor may focus on a lymph node biopsy instead. However, a bone marrow biopsy is important for staging your disease—understanding how far it has spread—and some clinical trials require it as part of their enrollment criteria. It can also explain symptoms like severe fatigue or anemia if lymphoma cells are crowding out normal blood cells in the marrow.[17][7]

What does it mean if my lymphoma is “grade III”?

The grade of follicular lymphoma refers to how many large, abnormal cells called centroblasts are seen under the microscope. Grade I and II lymphomas have fewer large cells and typically grow more slowly. Grade III has more large cells and is further divided into grade IIIA (which still has some smaller cells mixed in) and grade IIIB (which has sheets of large cells). Grade IIIB tends to behave more like an aggressive lymphoma and may be treated similarly to diffuse large B-cell lymphoma, while grades I, II, and IIIA are usually grouped together as indolent lymphomas.[13][5]

Can imaging tests alone tell my doctor if my follicular lymphoma has come back?

Imaging tests like CT scans and PET scans can show that lymph nodes are growing or new areas of abnormal activity have appeared, which strongly suggests the lymphoma has returned. However, enlarged lymph nodes can also be caused by infections or other conditions, and some scar tissue from previous treatment can light up on PET scans without being active cancer. That’s why doctors often recommend a biopsy to confirm that what they see on imaging is truly relapsed lymphoma and not something else.[17][1]

What tests do I need if I want to join a clinical trial for my refractory follicular lymphoma?

Clinical trials typically require a recent biopsy confirming your follicular lymphoma diagnosis, imaging scans (CT and/or PET) showing how much disease you have and where it’s located, blood tests checking your organ function and blood counts, a bone marrow biopsy to determine if cancer has spread there, and documentation of your previous treatments and how you responded to them. You’ll also need a physical exam assessing your ability to function in daily life (performance status). Some trials testing targeted therapies may require special molecular tests to see if your cancer has specific genetic changes that the treatment targets.[12][1]

🎯 Key Takeaways

  • • People whose follicular lymphoma returns within 24 months of chemotherapy or 12 months of rituximab treatment face a more challenging prognosis with a five-year survival rate of about 50 percent, making early detection of relapse critically important.
  • • A fresh lymph node biopsy when disease relapses can reveal whether follicular lymphoma has transformed into a more aggressive cancer type, fundamentally changing the treatment approach needed.
  • • The genetic change t(14;18), found in about 85-90 percent of follicular lymphomas, exists in small numbers of cells in some healthy people who never develop cancer, showing that multiple genetic “hits” are needed for the disease to actually appear.
  • • Not all relapsed follicular lymphoma requires immediate treatment—if you have no symptoms and feel well, your doctor may recommend active surveillance with regular monitoring rather than starting therapy right away.
  • • Clinical trials for refractory disease often require extensive diagnostic workup including recent biopsies, staging scans, blood tests, bone marrow examination, and sometimes special molecular testing to identify specific genetic features in cancer cells.
  • • PET scans can show metabolic “hot spots” where cancer cells are most active, but they can also light up with inflammation or scar tissue, which is why biopsy confirmation remains the gold standard for diagnosing relapse.
  • • The grade of follicular lymphoma (I, II, IIIA, or IIIB) determined by counting large cells under the microscope helps predict disease behavior, with grade IIIB acting more like aggressive lymphoma than its slower-growing counterparts.
  • • Even though follicular lymphoma is generally incurable, survival rates have dramatically improved since the introduction of rituximab and newer therapies, with median survival now extending beyond 14 years and many patients living much longer.

Connected medications: